# Samsung Biologics Listed on Dow Jones Best-in-Class World Index for Fifth Consecutive Year

- Link: https://www.thailand-business-news.com/pr-news/samsung-biologics-listed-on-dow-jones-best-in-class-world-index-for-fifth-consecutive-year
- Published: 2026-05-05T18:00:00+07:00
- Author: PR Newswire

|   |

 ◦ Marks five consecutive years of inclusion, reflecting continued progress in ESG
   management and execution
 ◦ Recognition highlights proactive alignment with evolving expectations from global
   stakeholders

INCHEON, South Korea, May 5, 2026 /PRNewswire/ — Samsung Biologics (KRX: 207940.
KS), a leading contract development and manufacturing organization (CDMO), announced
that it has been included in the Dow Jones Best-in-Class World Index (formerly the
Dow Jones Sustainability Index) for the fifth consecutive year, reaffirming the 
company’s continued commitment to sustainable growth and responsible business practices.

The annual index review is based on S&P Global Corporate Sustainability Assessment(
CSA), a globally recognized benchmark that evaluates over 2,500 companies across
a broad range of environmental, social, and governance (ESG) criteria, including
risk management and operational performance. Companies ranked within the top tier
of their respective industries are selected for index inclusion.

Samsung Biologics was recognized for its dedication to improving its overall performance
through enhanced sustainability data disclosures and the continued advancement of
ESG management practices. The company delivered strong results across key areas,
including supply chain management, environmental stewardship, and workplace health
and safety. These outcomes demonstrate the company’s ability to embed ESG considerations
across its operations and business practices.

"This recognition acknowledges our steady progress in strengthening the sustainability
management framework across all areas of the business," said John Rim, President
and CEO of Samsung Biologics, who also serves as a champion of the Sustainable Markets
Initiative (SMI) Supply Chains Working Group. "We remain committed to responsible
growth, transparent operations, and long-term value creation for clients, communities,
and stakeholders."

The continued inclusion also underscores Samsung Biologics’ proactive response to
evolving expectations from global investors and stakeholders, while providing objective
recognition of the company’s sustainability performance. Samsung Biologics continues
to advance its ESG initiatives through disciplined execution, responsible operations,
and transparent governance. This year, the company received an EcoVadis Platinum
rating and also won a sustainability award at the CDMO Leadership Awards.

**About Samsung Biologics **

Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing
organization (CDMO), offering end-to-end integrated services that range from late
discovery to commercial manufacturing.

With a combined biomanufacturing capacity of 785,000 liters across Bio Campuses 
I and II in Korea, and 60,000 liters from its manufacturing facility in Rockville,
Maryland, U.S., Samsung Biologics holds a total global manufacturing capacity of
845,000 liters. The company has also secured land for Bio Campus III, laying the
groundwork for future capacity expansion to support next-generation therapies and
emerging modalities.

Samsung Biologics’ global manufacturing and commercial network spans Korea, the 
U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and
Europe, while its Tokyo- and Songdo-based sales offices serve the APAC region.

Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse
modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates,
and mRNA therapeutics. By implementing its ExellenS™ framework across its manufacturing
network with standardized designs, unified processes, and advanced digitalization,
Samsung Biologics ensures plant equivalency and speed for manufacturing continuity.

Samsung Biologics continues to invest in new capabilities to maximize operational
and quality excellence, ensuring flexibility and agility for clients. The company
is committed to the on-time, in-full delivery of safe, high-quality biomedicines,
as well as to making sustainable business decisions for the betterment of society
and global health.

For more information, visit [https://samsungbiologics.com/](https://samsungbiologics.com/).

**Media contacts**

Claire Kim, Senior Director [cair.kim@samsung.com](https://www.thailand-business-news.com/pr-news/cair.kim@samsung.com)

Becky Lee, Director [brite.lee@samsung.com](https://www.thailand-business-news.com/pr-news/brite.lee@samsung.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Samsung Biologics Listed on Dow Jones Best-in-Class World Index for Fifth Consecutive Year ](http://www.prnasia.com/story/archive/4951316_CN51316_0?rand=184833)